SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934

(Amendment No. 4)*

Landos Biopharma, Inc.

(Name of Issuer)

Common Stock, $0.01 par value

(Title of Class of Securities)

515069201

(CUSIP Number)

Christopher Garabedian

Xontogeny, LLC

361 Newbury Street, Suite 501

Boston, MA 02115

(857) 891-0017

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

March 24, 2024

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 515069201


1.		Names of Reporting Persons. Xontogeny, LLC
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
3.		SEC Use Only
4.		Source of Funds (See Instructions) WC
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware

Item 2.

Identity and Background

Item 2 of the Schedule 13D is amended and supplemented as follows:

The address of the principal business office of Xontogeny is 361 Newbury Street, Suite 501 Boston, MA 02115.

Item 4.

Purpose of Transaction

Item 4 of the Schedule 13D is amended and supplemented as follows:

The information set forth below in Item 6 in this Amendment No. 4 is incorporated by reference to this Item 4.

Item 5.

Interest in Securities of the Issuer

Item 5 of the Schedule 13D is amended and supplemented as follows:

(a)

The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D/A is incorporated by reference. The percentage set forth in row 13 is based on 3,116,729 outstanding shares of Common Stock as reported by the Issuer in its Form 10-K filed with the Securities and Exchange Commission on March 21, 2024, and give effect to the Issuer’s 10-for-1 reverse stock split effected on May 25, 2023 (the “Reverse Stock Split”).

(b)

The information set forth in rows 7 through 10 of the cover page to this Schedule 13D/A is incorporated by reference, and give effect to the Issuer’s Reverse Stock Split.

Item 6.

Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

Item 6 of the Schedule 13D is amended and supplemented as follows:

Voting Agreement

On March 24, 2024, the Issuer entered into an agreement and plan of merger (the “Merger Agreement”) by and among the Issuer, Bespin Subsidiary, LLC, (the “Parent”), a Delaware corporation and a wholly owned subsidiary of AbbVie Inc., and Bespin Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (the “Merger Sub”), providing for, among other things, the merger of Merger Sub with and into the Issuer (the “Merger”), with the Issuer surviving the Merger as a wholly owned subsidiary of the Parent. On March 24, 2024, concurrent with the execution and delivery of the Merger Agreement, Xontogeny entered into a voting agreement (the “Voting Agreement”) with the Issuer, Parent and Perceptive Advisors LLC, pursuant to which each of Xontogeny and Perceptive Advisors, including their respective affiliates, agreed to (i) vote their shares of Common Stock (such shares, the “Restricted Shares”), in favor of the adoption of the Merger Agreement and against any alternative acquisition proposals, (ii) refrain from engaging in certain solicitation activities that may be reasonably expected to constitute or result in any alternative acquisition proposal, and (iii) refrain from (a) transferring, selling, assigning, gifting, hedging, pledging or otherwise disposing of, or entering into any derivative arrangement with respect to their Restricted Shares, or any rights or interests therein (or consenting to any of the foregoing), (b) entering into any contract, option or other agreement, arrangement or understanding with respect to any transfer of Restricted Shares or any interests therein, (c) granting or permitting the grant of any proxy, power-of-attorney or other authorization or consent in or with respect to their Restricted Shares or (d) depositing or permitting the deposit of any of their Restricted Shares into a voting trust or enter into a voting agreement or arrangement with respect to any of such Restricted Shares, in a manner that would adversely affect their ability to perform their obligations under the Voting Agreement.

The description of the Voting Agreement set forth above in this Item 6 does not purport to be complete and is qualified in entirety by reference to the full text of the Voting Agreement, which is attached to this Amendment No. 4 as Exhibit 3, and incorporated by reference herein.

Item 7.

Material to be Filed as Exhibits

Item 7 of the Schedule 13D is amended and supplemented as follows:


		Exhibit 3		Voting Agreement, dated as of March 24, 2024, by and among Landos Biopharma, Inc., Xontogeny, LLC and Perceptive Advisors LLC (incorporated by reference to Exhibit 10.1 to the Issuer’s Current Report on Form 8-K filed on March 25, 2024).

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: April 10, 2024


XONTOGENY, LLC

By:		/s/ Christopher Garabedian
		Name: Christopher Garabedian
		Title: Chairman and Chief Executive Officer

Number of

Shares Beneficially

Owned by

Each

Reporting

Person

With

Sole Voting Power

0

Shared Voting Power

309,092

Sole Dispositive Power

0

Shared Dispositive Power

309,092

Landos Biopharma, Inc. SC 13D/A